Lexeo Therapeutics, INC Form 4 insider transactions

Sandi See Tai, Chief Development Officer of Lexeo Therapeutics, sold 1,486 shares of common stock to cover tax obligations related to the release of restricted stock units.

Eric Adler, Chief Medical Officer of Lexeo Therapeutics, sold 2,359 shares of common stock on February 19, 2025, to cover tax obligations related to the release of restricted stock units.

Jenny Robertson, Chief Legal Officer of Lexeo Therapeutics, sold 2,101 shares of common stock on February 19, 2025, to cover tax obligations related to the release of restricted stock units.

Chief Financial Officer Kyle Rasbach of Lexeo Therapeutics reports the acquisition of restricted stock units and stock options.

Richard Nolan Townsend, CEO of Lexeo Therapeutics, reports acquisition of shares and stock options.

Jose Manuel Otero, Chief Technical Officer of Lexeo Therapeutics, reports acquisition of stock options and restricted stock units (RSUs) in a recent SEC filing.

Jenny Robertson, Chief Legal & Admin Officer of Lexeo Therapeutics, reports acquiring and disposing of common stock and stock options in a transaction dated January 7, 2025.

Chief Development Officer Sandi See Tai reports the acquisition of stock options and restricted stock units in Lexeo Therapeutics.

Eric Adler, Chief Medical Officer of Lexeo Therapeutics, reports acquisition and disposal of common stock and stock options.

Lexeo Therapeutics CEO Richard Nolan Townsend exercised stock options and sold shares under a pre-arranged 10b5-1 trading plan.

Paula H Cholmondeley, a director at Lexeo Therapeutics, acquired 15,000 shares of common stock at a price of $6.9901 per share on November 25, 2024.

Tolga Tanguler, a director at Lexeo Therapeutics, acquired 36,000 stock options on November 11, 2024, at an exercise price of $7.95.

Lexeo Therapeutics CEO Richard Nolan Townsend exercised stock options and sold shares under a pre-arranged 10b5-1 trading plan.

CEO Richard Nolan Townsend exercised stock options and sold shares of Lexeo Therapeutics under a pre-arranged Rule 10b5-1 trading plan.

Lexeo Therapeutics CEO Richard Nolan Townsend exercised stock options and sold 5,000 shares of common stock at an average price of $10.6547, according to a recent SEC filing.

CEO Richard Nolan Townsend exercised stock options and sold shares of Lexeo Therapeutics under a pre-arranged Rule 10b5-1 trading plan.

Richard Townsend, CEO of Lexeo Therapeutics, executed options and sold shares of common stock under a pre-arranged Rule 10b5-1 trading plan.

Director Timothy Van Hauwermeiren acquired stock options in Lexeo Therapeutics, Inc. on July 5, 2024.

Director Brenda Cooperstone reports the acquisition of stock options in Lexeo Therapeutics.

Director Steven Altschuler receives stock options in Lexeo Therapeutics, signaling continued involvement with the company.

Director Reinaldo Diaz of Lexeo Therapeutics acquired 18,000 stock options on June 25, 2024, according to a Form 4 filing with the SEC.

Director Paula Cholmondeley reports the acquisition of stock options in Lexeo Therapeutics.

Mette Kirstine Agger, a director of Lexeo Therapeutics, acquired 18,000 stock options on June 25, 2024, according to a Form 4 filing with the SEC.

Jose Manuel Otero, Chief Technical Officer of Lexeo Therapeutics, acquired stock options and restricted stock units (RSUs) as part of an equity grant.

Lexeo Therapeutics CEO Richard Townsend executed stock options and sold shares under a pre-arranged Rule 10b5-1 trading plan.

Lexeo Therapeutics CEO Richard Nolan Townsend exercised stock options and sold 5,000 shares of common stock on May 13, 2024, under a pre-arranged Rule 10b5-1 trading plan.